Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in-Human, Multicenter, Open-Label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 as Monotherapy and in Combination With Toripalimabin Subjects With Advanced Solid Malignancies Including Lymphoma

Next Previous
Search
Trial Profile

A First-in-Human, Multicenter, Open-Label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 as Monotherapy and in Combination With Toripalimabin Subjects With Advanced Solid Malignancies Including Lymphoma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tifcemalimab (Primary) ; Toripalimab (Primary)
  • Indications Lymphoma; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; First in man
  • Sponsors Shanghai Junshi Biosciences

Most Recent Events

  • 04 Jun 2024 Results (n=85; by 16 Dec 2023) reporting dose escalation and cohort expansion data presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
  • 06 Jun 2022 According to Junshi Biosciences media release, results presented at at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top